lobbying_activities: 3010669

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3010669	38721f94-9c39-4b68-a6a1-17ed4dff9038	Q2	MEHLMAN CONSULTING, INC.	284950	THE CAMPAIGN FOR SUSTAINABLE RX PRICING	2023	second_quarter	CPT	Patent abuse issues. S. 150 - Affordable Prescriptions for Patients Act of 2023. S. 79 - Interagency Patent Coordination Act. Initiatives To Ensure the Robustness and Reliability of Patents Rights (PTO-P-2022-0025). Joint USPTO-FDA Collaboration Initiatives. Notice of Public Listening Session and Request for Comment (PTO-P-2022-0037).	Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Patent & Trademark Office (PTO),SENATE	50000		0	0	2023-07-18T14:24:02-04:00